Effect of Y virilin on male infertility.

• Main Authors: Rege N, Date J, Kulkarni V, Prem A, Punekar S, Dahanukar S
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 1997-07-01
• Series: Journal of Postgraduate Medicine
• Subjects: Double-Blind Method; Follicle Stimulating Hormone; blood; Human; Male; Oligospermia; drug therapy; Phytotherapy; Prospective Studies; Sperm Count; drug effects
• Online Access: http://www.jpgmonline.com/article.asp?issn=0022-3859;year=1997;volume=43;issue=3;spage=64;epage=7;aulast=Rege
• ISSN: 0022-3859; 0972-2823

A prospective placebo controlled double blind study was conducted in patients attending male infertility clinics of our hospital to evaluate effects of a herbal formulation for male infertility--′Y-virilin′. In phase 1 forty patients with oligospermia with or without asthenospermia were randomly allocated to 2 treatment groups--Treatment Group A i.e. formulation under test and treatment Group B (Placebo). Therapy with these agents was given twice a day for 6 months. In phase 2, 12 patients with azospermia were administered either ′Y virilin′ or the placebo (n = 6/Gp). In all patients along with semen analysis (sperm count, percentage of motile sperms and grade of motility) was done monthly for 6 months. Serum FSH levels were estimated before and at the end of therapy. A significant increase in sperm count was observed from 2-3 months in oligospermics receiving Y virilin as compared to basal values (p < 0.05). In Group B the follow-up sperm counts were either comparable to basal values or were lesser. However, the percentage and grade of motility did not differ in two groups at the end of respective treatment. No change was found in mean FSH value. During the therapy period incidence of conception was 20% in treatment Group A and 5% in Group B. Of the azospermic receiving ′Y-virilin′ 50% showed a count of 10-20 millions/cmm while none from the placebo group. This study highlights the therapeutic potential of the tested formulation in the patients with infertility.